Medical Device News Magazine

Alife Launches New AI Platform to Optimize IVF

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Alife Health announced the launch of its Alife Assist™ platform today. This new suite of products aims to help fertility clinics utilize and leverage data-driven insights and artificial intelligence (AI) to optimize and support clinical decision-making during critical stages of the in-vitro fertilization (IVF) process, as well as streamline overall clinic operations. This marks the company’s official entry into the clinical market after conducting two years of research and development with its notable list of clinic partners, advisors, and investors.

“I founded Alife because I knew that AI has the potential to drastically impact the IVF process. Yet, as we began to work with fertility clinics around the country, we quickly identified a parallel opportunity for improvement: the need for a central platform to digitize clinic workflow and support collective decision-making. Our team is thrilled to launch Alife Assist™, a first-of-its-kind product suite that optimizes the IVF process from end-to-end,” says Paxton Maeder-York, CEO of Alife. “Together, our products will help clinics harness the power of AI and advanced analytics to streamline their workflow and bring a more personalized experience to their patients.”

“AI has enormous potential to help inform our decisions as clinicians. When it comes to patient care decision making, the more data and information, the better. If we can harness the knowledge of thousands of past patient cycles from clinics around the world, we can make more informed choices about the patient sitting right in front of us,” says Louis Weckstein, MD.

The Alife Assist™platform is made up of three robust products that are supported by the team’s scientific research and collaboration with top clinics:

  • Stim Assist™ is a set of AI-powered clinical decision support tools that helps reproductive endocrinologists choose the optimal medication dose and timing to maximize the number of mature eggs retrieved from an ovarian stimulation cycle. These tools use one of the largest and most diverse IVF datasets in the world which contains millions of rows of historical data from previous patient cycles to provide insights on what treatment has worked best for similar patients. Alife’s research indicates that in general more mature oocytes are associated with a higher live birth percentage
  • Embryo Assist™ streamlines and enhances an embryologist’s workflow in a single tool to keep consistent records, save time, and automate reports. This enables embryologists to digitally capture, grade, organize, and report embryo grading data like never before, all with real-time EMR connection.
  • Insights™ is an analytics dashboard that gives directors, managers, and administrators the ability to monitor and visualize their clinic’s performance in real-time. This simplifies the process of extracting trends and sharing reports to optimize overall clinic operations.

Alife Assist™ is now available for IVF clinics in the United States.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”